z-logo
Premium
Level of neutral alpha‐1,4‐glucosidase in seminal plasma of Chinese men
Author(s) -
Qiu Z.,
Chu Q.,
Zhang W.,
Luo C.,
Quan S.
Publication year - 2018
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.12948
Subject(s) - male infertility , semen , asthenozoospermia , andrology , infertility , oligospermia , semen quality , semen analysis , medicine , epididymis , azoospermia , gynecology , sperm , biology , pregnancy , genetics
Summary Neutral alpha‐1,4‐glucosidase ( NAG ) is a crucial biomarker for the function of epididymis and is reported to be associated with semen quality. However, the correlation between NAG and Chinese semen quality has never been reported. This study aimed to investigate the level of NAG in the seminal plasma of Chinese men. A total of 394 cases of seminal plasma samples from normal, subfertile and infertile men were enrolled in this study. Male subfertility was caused by teratozoospermia, asthenospermia, severe oligozoospermia, asthenoteratozoospermia, oligoasthenospermia and oligoasthenoteratozoospermia. Male infertility was resulted from azoospermatism. The level of NAG was detected by spectrophotometry. Results showed that the level of NAG in normal men was significantly higher than that in subfertile and infertile men ( p  =   .000). Meanwhile, the level of NAG in subfertile men was significantly greater than that in infertile men ( p  =   .000). In addition, a significant difference was observed in normozoospermia, teratozoospermia, asthenospermia, severe oligozoospermia, asthenoteratozoospermia, oligoasthenospermia, oligoasthenoteratozoospermia and azoospermatism ( p  <   .05). In conclusion, these data indicate that NAG is a crucial marker for assessing seminal plasma quality in Chinese men, which might be helpful for the assistant diagnosis of male infertility.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here